According to a report, a European drug regulator is examining blood clots in four people in the United States who have received Johnson & Johnson’s COVID-19 vaccine.
The European Medicines Agency said three serious cases of coagulation and low platelets occurred in the US during the introduction of the J&J vaccine from its Janssen unit, and one person died of a coagulation disorder reported in a clinical trial. The EMA report is the first to report a probe of blood clots associated with the J&J vaccine.
Johnson & Johnson said it was aware of the rare reports of blood clots and was working with regulators.
“Currently, there is no clear causal link between these rare events and the Janssen COVID-19 vaccine,” the company said in a statement to Reuters.
The Food and Drug Administration said it was aware of the blood clot problem and had also found no “causal link to vaccination.”
As of Thursday morning, nearly 5 million people in the United States had received the J&J vaccine, according to the U.S. Centers for Disease Control and Prevention.
The issue of blood clots in the brain, reported by some in Europe who have received the AstraZeneca vaccine, is also being investigated.